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INTRODUCTION
The onset of coronary artery aneurysm (CAA) after drug-elut-
ing stent (DES) implantation is uncommon, with an incidence 
ranging from 0.8% to 1.3%. However, associated adverse clini-
cal events may present as a result of DES thrombosis and re-
stenosis.1-4 Furthermore, the occurrence of DES thrombosis 
appears to be particularly high in patients with CAA who dis-
continued dual-antiplatelet therapy.4 Importantly, most pre-
vious studies have been conducted involving patients treated 
with first-generation DES implantation alone and, although 
concerns about the development of CAA after DES implanta-
tion have decreased after the introduction of second-genera-
tion DESs, occurrences of CAA even after second-generation 
DES implantation have been reported in recent case reports.5-7 
At this time, to our knowledge, the incidence of CAA after sec-
ond-generation DES implantation has not been evaluated, and 
even more concerning, the clinical implications of angiograph-
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ic CAA after second-generation DES placement remain un-
certain. Therefore, we sought to evaluate the incidence and 
predictors of CAAs after second-generation DES implantation 
and to compare clinical outcomes in these patients with those 
of patients with CAAs after first-generation DES implantation 
using data from our CAA registry.4
MATERIALS AND METHODS
Study population
This study was a single-center, retrospective, observational 
study. Between August 2006 and August 2018, a total of 11982 
consecutive patients underwent second-generation DES im-
plantation (Fig. 1). Of these 11982 patients, 976 patients (8.1%) 
with 1245 lesions underwent follow-up angiography within 2 
years of second-generation DES placement, including 816 pa-
tients (83.6%) for routine follow-up without any symptoms and 
160 patients (16.4%) for the evaluation of newly-developed 
symptoms, respectively. To compare with CAAs after first-gen-
eration DES implantation, angiographic data and clinical out-
comes of 34 first-generation DES-related CAAs were obtained 
from our previous CAA registry data (Fig. 1).4 Briefly, these 
registry data from four independent referral hospitals in South 
Korea included 3612 consecutive patients (4419 lesions) with 
late angiographic follow up after first-generation DES implan-
tation, which represented 58.4% of the larger initial population. 
In this subpopulation, 34 CAAs (0.77%) in 29 patients (0.80%) 
were detected during late follow-up angiography.4 This study 
was approved by the Institutional Review Board of Severance 
Hospital, Yonsei University Health System (No.: 4-2018-0759).
Intervention procedure
Stent implantation was performed according to current stan-
dard techniques and medical guidelines. A total of 1245 lesions 
were treated with second-generation DESs: 425 everolimus-
eluting (Xience, Abbot Vascular, Santa Clara, CA, USA; and 
Promus, Boston Scientific, Marlborough, MA, USA), 399 zo-
tarolimus-eluting (Endeavor Resolute, Medtronic, Minneapo-
lis, MN, USA), 89 sirolimus-eluting (Orsiro, Biotronik, Berlin, 
Germany), and 332 biolimus-eluting (BioMatrix, Biosensors 
International, Singapore; and Nobori, Terumo, Tokyo, Japan) 
stents were used.
All patients were given 300 mg of aspirin in addition to 300 
mg to 600 mg of clopidogrel, 180 mg of ticagrelor, or 60 mg of 
prasugrel before their procedure and were maintained on dual-
antiplatelet therapy after DES implantation for at least 6 months. 
During the intervention, unfractionated heparin was adminis-
tered to maintain an activated clotting time of more than 250 
seconds. Specific details of the intervention, such as lesion pre-
dilatation, poststent dilation, and the application of mechani-
cal support or concomitant medication, were left to the dis-
cretion of the operator.
Definition and clinical follow up
A dilatation of a major epicardial, stented coronary artery that 
exceeded the diameter of the normal adjacent reference ves-
sel by 1.5 times that was closely related to the underlying DES 
or its edges and was not present immediately after the proce-
dure was defined as CAA.1,4 According to a previous study,4 CAAs 
can be classified into three different types: (1) ectatic type, a 
diffuse aneurysmal dilatation of the coronary artery that in-
volves more than 50% of the stent length; (2) fusiform type, a 
spindle-shaped dilatation (along the axis of a vessel with at 
least twice the diameter of the transverse dimension); and (3) 
saccular type, a single or multiple spherical-shaped dilatation 
(the transverse dimension is usually greater than the longitu-
dinal dimension).4 
A total of 11982 patients received
second-generation DESs
between Aug 2006 and Aug 2018
6176 patients received
first-generation DESs
(from our CAA registry data)*
976 patients (1245 lesions) underwent
follow-up angiography
3612 patients (4419 lesions)
underwent follow-up angiography
Patients with CAAs
after second-generation DES
10 CAAs/10 patients
Patients with CAAs
after first-generation DES
34 CAAs/29 patients
Patients without CAAs
after second-generation DES
1235 lesions/966 patients
Fig. 1. Study population. *Angiographic data and clinical outcomes of 34 coronary artery aneurysms (CAAs) after first-generation drug-eluting stent (DES) 
were obtained from our CAA registry data. Aug, August.
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A major adverse cardiac event (MACE) was defined as a com-
posite of cardiac death, myocardial infarction, and stent thrombo-
sis. All deaths were considered cardiac deaths unless a definite 
noncardiac cause could be established. After hospital discharge, 
myocardial infarction was defined as the presence of consis-
tent clinical symptoms, electrocardiographic changes, or ab-
normal imaging findings in combination with a creatine kinase 
myocardial band fraction increase of greater than the upper 
normal limit or an increase in troponin T or troponin I to more 
than the 99th percentile of the upper normal limit.8,9 The Aca-
demic Research Consortium definition of definitive or proba-
ble stent thrombosis was used.4,8
Statistical analysis 
Continuous variables are reported as a mean±standard devia-
tion or median (interquartile range) as appropriate and were 
compared using Student’s t-test or the Mann-Whitney U test. 
Categorical variables are reported as either a number or num-
ber (percentage) and were compared using Fisher’s exact test 
or the chi-squared test. Adverse event rates were compared 
using a log-rank test. Findings were considered significant at 
p<0.05. All statistical analyses were performed using the Sta-
tistical Package for the Social Sciences, version 18.0 (SPSS 
Inc., Chicago, IL, USA).
RESULTS
Among 976 consecutive patients (1245 lesions) who under-
went follow-up angiography, a total of 10 CAAs (0.80% per le-
sion) in 10 patients (1.02% per patient) were detected at follow-
up after second-generation DES implantation with a median 
implanted time of 329 days (interquartile range: 210–403 days). 
The individual profiles and angiographic morphologies of 
these patients with CAA are shown in Table 1 and Fig. 2. The in-
cidence of CAA after second-generation DES implantation was 
similar to that of CAA after first-generation DES implantation 
according to our previous registry data (0.77% per lesion and 
0.80% per patient).4
Clinical characteristics between the patients with CAA (n=10) 
and those without CAA (n=966) after second-generation DES 
placement are presented in Table 2. There were no statistically 
significant differences in clinical characteristics between the 
two groups. Angiographic and procedural characteristics be-
tween the lesions with and without CAA after second-genera-
tion DES implantation are also presented in Table 3. In com-
parison with the lesions without CAA, those with CAA had more 
proximal lesions than mid-to-distal lesions (90% vs. 51%, p= 
0.014), a higher proportion of pre-intervention Thrombolysis 
in Myocardial Infarction (TIMI) scores of 0 or 1 flow (80% vs. 
16%, p<0.001), and more chronic total occlusions (40% vs. 10%, 
p<0.001). Also, total stent length was significantly longer in the 
lesions with CAA versus those without CAA (41.9±23.2 mm vs. 
28.8±14.8 mm, p=0.006). When compared to the lesions with 
CAA after first-generation DES implantation (n=34) (Table 4), 
those with CAA after second-generation DES implantation had 
a significantly higher proportion of pre-intervention TIMI scores 
of 0 or 1 flow (80% vs. 12%, p<0.001), more chronic total occlu-
sions (40% vs. 9%, p=0.018), and longer total stent length (41.9± 
23.2 mm vs. 28.0±5.0 mm, p=0.002).
Table 1. Individual Profiles of 10 CAAs after Second-Generation DES Implantation
Case No.
1 2 3 4 5 6 7 8 9 10
Age (yr) 64 50 71 43 73 42 89 67 72 60
Sex M M F M F M M F F F
Clinical diagnosis at index PCI SA STEMI SA SA UA STEMI STEMI SA SA NSTEMI
Treated coronary artery RCA LCX LAD RCA RCA LAD RCA RCA LAD RCA
Proximity of lesions Yes Yes Yes Yes Yes No Yes Yes Yes Yes
ACC/AHA lesion classification C C C C C C B2 C C C
Chronic total occlusion Yes No Yes Yes No No No Yes No No
Days from index PCI to diagnosis of CAA 368 264 289 385 412 79 69 210 403 588
Morphology of CAA Fusiform Fusiform Fusiform Fusiform Fusiform Multiple 
saccular
Fusiform Fusiform Fusiform Fusiform
Location of CAA relative to stent Mid Mid Mid Mid Proximal 
edge
Mid Proximal 
edge
Mid Proximal 
edge
Mid
Follow-up days after diagnosis of CAA 1594 2517 1574 2732 2306 1849 1044 1363 1013 515
Days of maintained dual-antiplatelet 
  therapy after diagnosis of CAA
0* 925 43 428* 0* 372 598 15 574 105
CAA, coronary artery aneurysm; DES, drug-eluting stent; M, male; F, female; PCI, percutaneous coronary intervention; SA, stable angina; STEMI, ST-elevation 
myocardial infarction; UA, unstable angina; NSTEMI, non-ST-elevation myocardial infarction; RCA, right coronary; LCX, left circumflex; LAD, left anterior de-
scending; ACC/AHA, American College of Cardiology/American Heart Association.
*Patients were maintained on mono-antiplatelet therapy at the time of CAA detection.
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As for CAA morphology, the predominant form of CAA af-
ter second-generation DES implantation was significantly dif-
ferent from that of CAA after first-generation DES implanta-
tion (p<0.001) (Table 4, Fig. 3A). CAAs after second-generation 
DES placement were predominantly of the single fusiform type 
(90%), whereas CAAs after first-generation DES placement 
were multiple saccular (47%) and single saccular (35%) types.
The clinical outcomes of CAA according to DES generation 
are presented in Table 5 and Fig. 3B. During a median follow-
up of 309 days (interquartile range: 16–581 days) after CAA 
detection following first-generation DES implantation, a total 
of five cases with CAA (15%) experienced MACE.4 These five 
adverse events were related to acute myocardial infarction with 
definite or probable stent thrombosis.4 However, during a me-
dian follow-up of 1584 days (interquartile range: 1044–2306 
days), no patients with CAA had MACE, and one patient with 
CAA received target lesion revascularization at the time of 
CAA detection (case 4 in Table 1, Supplementary Fig. 1, only 
online). Thus, CAAs after first-generation DES implantation 
had significantly higher MACE rates than did those after sec-
ond-generation DES implantation (p value by log-rank=0.047). 
The duration of dual-antiplatelet therapy after CAA detection 
was not different between CAAs after second-generation DES 
implantation versus those after first-generation DES implan-
tation (p=0.847).
DISCUSSION
The major findings of our study are that (1) CAAs after second-
generation DES implantation were detected at incidence rates 
of 0.80% per lesion and 1.02% per patient, which were higher 
than values associated with CAA after first-generation DES im-
plantation; (2) after implantation of second-generation DESs, 
CAAs were more frequently detected in correlation with the 
treatment of more complex lesions (e.g., pre-intervention TIMI 
flow grade 0 or 1, chronic total occlusions, and longer implant-
ed stents); and (3) CAAs after second-generation DES implan-
tation had different morphologies and might have more favor-
able clinical outcomes, compared with those after first-generation 
DES implantation.
Table 2. Clinical Characteristics between Patients with and without 
CAAs after Second-Generation Drug-Eluting Stent Implantation
With CAA 
(n=10)
Without 
CAA 
(n=966)
p value
Age (yr) 63±15 63±11 0.944
Body mass index (kg/m2) 24.7±4.6 24.6±3.1 0.991
Men (n, %) 5 (50) 726 (75) 0.068
Hypertension (n, %) 5 (50) 640 (66) 0.280
Diabetes mellitus (n, %) 3 (30) 357 (37) 0.650
Chronic kidney disease (n, %) 0 38 (4) 0.522
Current smoker (n, %) 4 (40) 282 (29) 0.455
Dyslipidemia (n, %) 7 (70) 691 (72) 0.915
Left ventricular ejection fraction (%) 61.8±12.8 58.8±12.3 0.451
Clinical diagnosis at index procedure (n, %) 0.474
Stable angina 5 (50) 465 (48)
Unstable angina 1 (10) 213 (22)
Non-ST-elevation myocardial infarction 1 (10) 149 (16)
ST-elevation myocardial infarction 3 (30) 139 (14)
Severity of coronary artery disease (n, %) 0.685
1-vessel disease 1 (10) 166 (17)
2-vessel disease 3 (30) 347 (36)
3-vessel disease 6 (60) 453 (47)
CAA, coronary artery aneurysm.
Values are presented as mean±standard deviation or n (%) unless otherwise 
indicated.
Fig. 2. (A–J) Individual morphologies of 10 coronary artery aneurysms (CAAs) (Case 1 through Case 10) after second-generation drug-eluting stent (DES) 
implantation. White arrowheads indicate the development of CAAs. Detailed individual data are also presented in Table 1.
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Although the exact mechanisms remain unclear, several causes 
of CAAs have been suggested to date. The mechanical risk fac-
tors for CAAs after coronary intervention include arterial wall 
injury as well as dissection or rupture induced by high-pres-
sure balloon inflation or oversized stent. Atherectomy and laser 
angioplasty have additionally been associated with the devel-
opment of CAAs.10,11 Therefore, our findings of the predictors 
of CAAs after second-generation DES implantation, specifi-
cally more complex lesions, such as chronic total occlusions 
or those requiring longer stents, may be line with the suggest-
ed mechanisms. Similar to these findings, CAA development 
after first-generation DES placement was related to more se-
vere complex lesions. Our previous registry data also indicat-
ed that the CAA development after first-generation DES place-
ment occurs exclusively in complex (type B2/C) de novo lesions 
and that lesion length is significantly greater in patients with 
CAA than in those without CAA.4 Interestingly, when we com-
pared the observed CAAs present after second-generation DES 
implantation and those present after first-generation DES im-
plantation, the CAAs after second-generation DES placement 
also had more complex lesions than did those after first-gen-
eration DES placement.
Other factors for the development of CAAs have also been 
proposed due to DES implantation.1-4 DESs have been used for 
reducing restenosis by administration of cytotoxic anti-reste-
nosis drugs to inhibit endothelial cell and smooth muscle cell 
proliferation, and these antiproliferative effects have been sug-
gested to increase the risk of CAAs because of the mechanism 
of delayed neointimal healing and reendotheliazation.12,13 Sep-
arately, a local hypersensitivity reaction to the polymer of the 
drug in the DESs may contribute to CCAs. The inflammatory 
response to the drugs increased eosinophilic or heterophilic 
infiltration into the vessel, as well as the occurrence of local tox-
ic effects. These mechanisms induce weakening and disrup-
tion of the arterial wall, provoking arterial wall expansion and 
aneurysmal change.13-15 Although concerns about the develop-
ment of CAAs after DES placement have decreased with great-
er use of second-generation DESs, these limitations still can 
be related to CAA onset even in the context of second-genera-
tion DES implantation. In our study, we documented incidence 
rates of CAAs after second-generation DES implantation of 
0.80% per lesion and 1.02% per patient. According to previous 
reports on first-generation DESs, CAAs were detected with an 
incidence of 0.8% to 1.3%.1-4 Such numbers are relatively com-
parable to those regarding CAAs after second-generation DES 
use. However, importantly, different than the CAAs after first-
generation implantation, the CAAs after second-generation 
implantation had different predominant morphologies and 
more favorable outcomes, reflecting the advances in DES tech-
nology. According to recent studies involving first-generation 
DESs, CAAs are frequently associated with adverse clinical 
events as a result of DES thrombosis and restenosis.1-4 In one 
investigation, Alfonso, et al.1 found that, of 1197 patents with 
first-generation DESs, CAAs developed in 15 patients (1.25%) 
and the 1-year adverse event rate was 51%. Joo, et al.3 followed 
up 78 patients with CAA after first-generation DES implanta-
tion and determined that the patients with CAAs displayed a 
significantly higher incidence of MACE than did those with-
out CAAs, driven by target-lesion revascularization and myo-
cardial infarction. Lastly, from our CAA registry of first-gener-
ation DESs, myocardial infarction with stent thrombosis occurred 
in 17.2% of the cases with CAA with 75% being on aspirin alone 
without clopidogrel.4 However, notably, all three of these stud-
ies were conducted in patients treated with first-generation 
DES placement.
Our current study has some limitations. First, although we 
Table 3. Angiographic Characteristics between Lesions with and with-
out CAAs after Second-Generation DES
With CAA  
(n=10)
Without 
CAA 
(n=1235)
p value
Treated coronary arteries (n, %) 0.250
Left main 0 72 (6)
Left anterior descending 3 (30) 526 (43)
Left circumflex 1 (10) 252 (20)
Right coronary 6 (60) 385 (31)
Proximity of lesions (n, %) 0.014
Proximal 9 (90) 632 (51)
Mid-to-distal 1 (10) 603 (49)
ACC/AHA lesion classification (n, %) 0.065
Type B1 0 100 (8)
Type B2 1 (10) 542 (44)
Type C 9 (90) 586 (47)
Pre-intervention TIMI flow grade (n, %) <0.001
0/1 8 (80) 193 (16)
2/3 2 (20) 1042 (84)
Use of rotablation (n, %) 0 17 (1) -
Bifurcation (n, %) 1 (10) 386 (31) 0.148
Chronic total occlusion (n, %) 4 (40) 117 (10) 0.001
Thrombus (n, %) 2 (20) 130 (11) 0.333
Total stent length 41.9±23.2 28.8±14.8 0.006
Total stent number (n, %) <0.001
1 5 (50) 1040 (84)
2 3 (30) 176 (14)
3 2 (20) 19 (2)
Mean stent diameter 3.10±0.37 3.06±0.41 0.784
Type of second-generation DES (n, %) 0.974
Everolimus-eluting stent 3 (30) 422 (34)
Zotarolimus-eluting stent 3 (30) 396 (32)
Sirolimus-eluting stent 1 (10) 88 (7)
Biolimus-eluting stent 3 (30) 329 (27)
CAA, coronary artery aneurysm; DES, drug-eluting stent; ACC/AHA, Ameri-
can College of Cardiology/American Heart Association; TIMI, Thrombolysis 
in Myocardial Infarction.
Values are presented as mean±standard deviation or n (%) unless otherwise 
indicated.
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enrolled consecutive patients with follow-up angiography in 
our study, the percentages and indications were not pre-spec-
ified and differed from the cohorts with CAAs after first-gen-
eration DES placement. Also, selection bias is inevitable be-
cause all patients did not undergo follow-up angiography in 
our study. Second, a relatively small number of patients was 
analyzed, necessitating a larger group of initial follow-up pa-
tients to be studied for further confirmation. Also, the follow-
up duration of the CAA after first-generation DES was shorter 
than that of the CAA after second-generation DES, because 
our previous CAA registry of the first-generation DES was not 
extended for longer follow up. Third, our patients did not un-
dergo invasive intracoronary imaging studies, though these 
studies would be helpful to observe the development of late-
acquired stent malapposition due to CAA.
In conclusion, CAAs after second-generation DES implan-
tation were detected rarely at a similar incidence to that of 
CAAs after first-generation DES implantation. However, pa-
tients with second-generation DESs might demonstrate more 
favorable clinical outcomes, compared to those after first-
generation DES implantation.
Table 4. Angiographic Characteristics between Lesions with CAAs after First-Generation DES and Second-Generation DES
CAA after second-generation DES (n=10) CAA after first-generation DES (n=34) p value
At index PCI
Treated coronary artery (n, %) 0.016
Left anterior descending 3 (30) 25 (74)
Left circumflex 1 (10) 0
Right coronary 6 (60) 9 (26)
Proximity of lesions (n, %) 0.275
Proximal 9 (90) 9 (26)
Mid-to-distal 1 (10) 25 (74)
ACC/AHA lesion classification (n, %) 0.553
Type B1 0 3 (9)
Type B2 1 (10) 5 (15)
Type C 9 (90) 26 (76)
Pre-intervention TIMI flow grade (n, %) <0.001
0/1 8 (80) 4 (12)
2/3 2 (20) 30 (88)
Chronic total occlusion (n, %) 4 (40) 3 (9) 0.018
Total stent length (mm) 41.9±23.2 28.0±5.0 0.002
Mean stent diameter (mm) 3.1±0.4 3.1±0.3 0.909
Stent type -
First-generation DES (n, %)
Sirolimus-eluting stent - 25 (74)
Paclitaxel-eluting stent - 9 (26)
Second-generation DES (n, %)
Everolimus-eluting stent 3 (30) -
Zotarolimus-eluting stent 3 (30) -
Sirolimus-eluting stent 1 (10) -
Biolimus-eluting stent 3 (30) -
At diagnosis of CAA
Days from PCI to CAA detection  
  [median (interquartile range)]
329 (210–403) 385 (260–481) 0.170
Morphologic classification (n, %) <0.001
Ectasia 0 3 (9)
Fusiform 9 (90) 3 (9)
Saccular
Single 0 12 (35)
Multiple 1 (10) 16 (47)
CAA, coronary artery aneurysm; DES, drug-eluting stent; PCI, percutaneous coronary intervention; ACC/AHA, American College of Cardiology/American Heart 
Association; TIMI, Thrombolysis in Myocardial Infarction.
Values are presented as mean±standard deviation or n (%) unless otherwise indicated.
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Table 5. Comparison of Clinical Outcomes between Patients with CAA after First-Generation DES and Those with CAA after Second-Generation DES
CAA after second-generation DES 
(n=10)
CAA after first-generation DES 
(n=34)
p value
Follow-up days after CAA detection [median (interquartile range)] 1584 (1044–2306) 309 (16–581) <0.001
Days of DAPT after CAA detection [median (interquartile range)] 239 (15–574) 161 (0–564) 0.843
Major adverse cardiac event (n, %) 0 5 (15) 0.047*
Cardiac death (n, %) 0 0 -
Acute myocardial infarction (n, %) 0 5 (15) 0.047*
ST-elevation myocardial infarction 0 2 -
Non-ST-elevation myocardial infarction 0 3 -
Definite or probable stent thrombosis (n, %) 0 5 (15) 0.047*
Target lesion revascularization (n, %) 1 (10) 5 (15) 0.291*
CAA, coronary artery aneurysm; DES, drug-eluting stent; DAPT, dual antiplatelet therapy.
Values are presented as n (%) unless otherwise indicated.
*By log-rank test.
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